Amgen Inc. AMGN NDXSPXR3KPHARMA

Healthcare · Drug Manufacturers - General · United States

https://www.amgen.com

Company Profile ↓

$437.23

+55.66% 1Y

Mkt Cap$235.98B

P/E27.14

P/B19.01

Div. Yield2.49%

52W High$444.12

52W Low$263.86

Book Value$21.62

EPS (TTM)$16.11

Company Overview

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 91.5%, reflecting efficient use of shareholder capital.

Healthy Margins

Maintains a net profit margin of 23.0%.

Dividend Income

Offers a dividend yield of 2.49%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $36.75B (+10.0% YoY); net profit $7.71B.
Trailing 12 Months Year-on-year growth — revenue +9.5%, earnings +64.9%.
5-Year Trend Long-term compounding — revenue CAGR 5.5%, profit CAGR 5.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	5.51%
1 Year:	9.50%

Compounded Profit Growth

5 Years:	5.55%
1 Year:	64.90%

Stock Price Performance

1 Year:	+55.66%
6 Months:	+19.91%
3 Months:	+25.80%
1 Month:	+8.63%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 96% of range

$263.86 $444.12

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)62.51 · Neutral

Price Performance

1M+8.63%

3M+25.80%

6M+19.91%

1Y+55.66%

Valuation vs Sector

P/E of 27.14 is above the sector median of 25.17 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Strong return on equity of 91.5%.
Excellent profit margin of 23.0%.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

27.14

Industry PE

25.17

Forward P/E

18.21

PEG Ratio

2.14

Book Value

$21.62

Price to Book

19.01

P/S

5.82

EV/EBITDA

15.37

Dividend Yield

2.49%

Growth (CAGR)

Revenue 5Y

5.51%

Profit 5Y

5.55%

Revenue (YoY)

9.50%

Earnings (YoY)

64.90%

Profitability & Returns

ROCE

13.95%

ROE

91.47%

ROA

8.67%

Profit Margin

22.95%

Op Margin

35.55%

Gross Margin

71.89%

EPS (Latest Qtr)

$4.37

EPS (TTM)

$16.11

Balance Sheet & Liquidity

Debt/Equity

4.90

Quick Ratio

0.95

Current Ratio

1.37

Debt

$57.30B

Total Assets

$95.64B

Current Assets

$31.48B

Working Capital

$3.57B

Ownership

Promoter Holding

0.22%

Chg in Prom Hold

0.01%

FII / Inst Holding

85.12%

Chg in FII Hold

0.01%

Financial Snapshot

Enterprise Value

$235.98B

Total Revenue (TTM)

$38.09B

EBITDA

$17.27B

Free Cash Flow

$8.65B

Operating Cash Flow

$12.48B

Shares Outstanding

539.71M

Gross Margin

71.89%

Payout Ratio

60.87%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	608.52	32.79	$225.00B	0.32%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.42B	-	5.90B	6.53B	6.71B	6.24B	6.59B	6.65B	6.11B	6.99B	6.90B	7.45B	8.39B	8.50B	8.15B	9.18B	9.56B	9.87B	8.62B	10.05B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.97B	3.01B	3.08B	2.98B	2.74B	-
Gross Profit	4.48B	4.26B	4.22B	4.42B	4.49B	4.60B	4.20B	4.55B	4.46B	4.51B	4.40B	4.66B	4.47B	4.91B	4.23B	4.56B	4.43B	4.63B	4.38B	4.42B	4.54B	4.74B	-	-	-	-	-	-	-	-	-	-	-	-	5.18B	6.17B	6.47B	6.89B	5.87B	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.00B	3.51B	3.95B	4.17B	3.21B	-
Operating Income	2.34B	-	2.40B	2.38B	2.53B	-	2.59B	2.70B	2.44B	-	2.73B	2.83B	2.32B	-	2.47B	2.68B	2.48B	-	2.35B	2.32B	2.45B	-	2.13B	828.00M	2.38B	2.50B	2.18B	2.66B	1.92B	2.68B	2.02B	991.00M	1.91B	2.05B	1.18B	2.66B	2.53B	2.72B	2.67B	3.51B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.08B	3.60B	5.91B	3.30B	3.86B	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	723.00M	694.00M	685.00M	653.00M	657.00M	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.97B	1.57B	3.92B	1.51B	2.08B	-
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	243.00M	136.00M	705.00M	181.00M	265.00M	-
Net Income	1.86B	1.80B	1.90B	1.87B	2.02B	1.94B	2.07B	2.15B	2.02B	-4.26B	2.31B	2.30B	1.86B	1.93B	1.99B	2.18B	1.97B	1.70B	1.82B	1.80B	2.02B	1.61B	1.65B	464.00M	1.88B	1.48B	1.32B	2.14B	2.84B	1.38B	1.73B	-113.00M	746.00M	2.83B	1.73B	1.43B	3.22B	1.33B	1.82B	2.38B
Diluted EPS	2.44	2.37	2.50	2.47	2.68	2.59	2.79	2.91	2.76	-5.89	3.25	3.48	2.86	3.01	3.18	3.57	3.27	2.85	3.07	3.05	3.43	2.76	2.83	0.81	3.31	2.68	2.45	3.98	5.28	2.57	3.22	-0.21	1.38	5.22	3.20	2.65	5.93	2.45	3.34	4.37

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	14.77B	15.00B	14.64B	15.05B	15.58B	17.27B	18.68B	20.06B	21.66B	22.99B	22.85B	23.75B	23.36B	25.42B	-	26.32B	28.19B	33.42B	36.75B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.41B	8.45B	12.86B	12.04B
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19.92B	19.74B	20.57B	24.71B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.35B	11.84B	13.31B	15.63B
Operating Income	3.98B	5.21B	5.51B	5.54B	4.31B	5.58B	5.87B	6.19B	8.47B	9.79B	9.97B	10.26B	9.67B	9.14B	-	9.57B	7.90B	7.26B	9.08B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12.17B	14.80B	13.36B	16.90B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.41B	2.88B	3.15B	2.75B
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.35B	7.86B	4.61B	8.98B
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	794.00M	1.14B	519.00M	1.26B
Net Income	3.08B	4.05B	4.61B	4.63B	3.68B	4.34B	5.08B	5.16B	6.94B	7.72B	1.98B	8.39B	7.84B	7.26B	-	6.55B	6.72B	4.09B	7.71B
Diluted EPS	2.74	3.77	4.51	4.79	4.04	5.52	6.64	6.70	9.06	10.24	2.69	12.62	12.88	12.31	-	12.11	12.49	7.56	14.23

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	36.43B	39.63B	43.49B	48.87B	54.30B	66.12B	69.01B	71.45B	77.63B	79.95B	66.42B	59.71B	62.95B	-	65.12B	97.15B	91.84B	90.59B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	22.19B	30.33B	29.03B	29.06B
Cash & Equivalents	1.28B	2.02B	1.77B	2.88B	3.29B	6.95B	3.26B	3.81B	3.73B	4.14B	3.24B	3.80B	6.95B	6.04B	6.27B	-	7.63B	10.94B	11.97B	9.13B
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.93B	9.52B	7.00B	6.22B
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.56B	7.27B	6.78B	9.57B
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	61.46B	90.92B	85.96B	81.93B
Current Liabilities	-	-	4.89B	3.87B	6.57B	5.75B	8.19B	7.95B	7.01B	8.66B	11.20B	9.02B	13.49B	12.84B	11.65B	-	15.69B	18.39B	23.10B	25.49B
Long Term Debt	-	-	-	10.60B	10.87B	21.43B	26.53B	29.62B	30.21B	29.18B	30.19B	34.19B	29.51B	26.95B	32.90B	-	37.35B	63.17B	56.55B	50.01B
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	38.95B	64.61B	60.10B	54.60B
Total Equity	19.84B	18.51B	20.89B	22.67B	23.94B	19.03B	19.06B	22.10B	25.78B	28.08B	29.88B	25.24B	12.50B	9.67B	9.41B	-	3.66B	6.23B	5.88B	8.66B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	534.00M	535.40M	537.00M	538.80M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	5.40B	5.99B	6.34B	5.79B	5.12B	5.88B	6.29B	8.95B	9.73B	10.35B	11.18B	11.30B	9.15B	10.50B	-	9.72B	8.47B	11.49B	9.96B
Investing Cash Flow	-1.99B	-3.17B	-3.20B	-4.15B	-786.00M	-9.99B	-8.47B	-5.75B	-5.55B	-8.66B	-4.02B	14.34B	5.71B	-5.40B	-	-6.04B	-26.20B	-1.05B	-1.94B
Financing Cash Flow	-2.67B	-3.07B	-2.02B	-1.23B	-674.00M	419.00M	2.73B	-3.27B	-3.77B	-2.60B	-6.59B	-22.49B	-15.77B	-4.87B	-	-4.04B	21.05B	-9.41B	-10.86B
Capital Expenditure	-1.27B	-672.00M	-530.00M	-580.00M	-567.00M	-689.00M	-693.00M	-718.00M	-594.00M	-738.00M	-664.00M	-738.00M	-618.00M	-608.00M	-	-936.00M	-1.11B	-1.10B	-1.86B
Free Cash Flow	4.13B	5.32B	5.81B	5.21B	4.55B	5.19B	5.60B	8.23B	9.14B	9.62B	10.51B	10.56B	8.53B	9.89B	-	8.79B	7.36B	10.39B	8.10B
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-360.00M	3.31B	1.03B	-2.84B
Share Buybacks	5.10B	2.27B	3.21B	3.79B	8.31B	4.61B	832.00M	138.00M	1.87B	2.96B	3.16B	17.79B	7.70B	3.49B	4.97B	6.36B	0	200.00M	0

Ratios (Annual)

Figures in %.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	75.7%	70.0%	61.5%	67.2%
Operating Margin %	26.9%	34.8%	37.6%	36.8%	27.7%	32.3%	31.4%	30.9%	39.1%	42.6%	43.6%	43.2%	41.4%	35.9%	-	36.3%	28.0%	21.7%	24.7%
Net Margin %	20.8%	27.0%	31.5%	30.7%	23.6%	25.2%	27.2%	25.7%	32.0%	33.6%	8.7%	35.3%	33.6%	28.6%	-	24.9%	23.8%	12.2%	21.0%
ROE %	16.6%	19.4%	20.3%	19.3%	19.4%	22.8%	23.0%	20.0%	24.7%	25.8%	7.8%	67.2%	81.1%	77.2%	-	179.0%	107.8%	69.6%	89.1%
ROCE %	-	16.5%	15.4%	15.0%	10.0%	12.1%	10.1%	10.0%	13.5%	14.7%	14.1%	19.4%	20.6%	17.8%	-	19.4%	10.0%	10.6%	13.9%

Shareholding Pattern

Insiders

0.22%

Institutions

85.12%

Public Float

85.31%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	9.13%	49.36M	$21.35B
2	Vanguard Capital Management LLC	6.52%	35.25M	$15.24B
3	State Street Corporation	5.65%	30.56M	$13.21B
4	Capital World Investors	5.38%	29.08M	$12.57B
5	Invesco Ltd.	3.02%	16.32M	$7.06B
6	Geode Capital Management, LLC	2.90%	15.70M	$6.79B
7	Charles Schwab Investment Management, Inc.	2.78%	15.03M	$6.50B
8	Vanguard Portfolio Management LLC	2.75%	14.85M	$6.42B
9	Morgan Stanley	2.53%	13.65M	$5.90B
10	Wells Fargo & Company	1.34%	7.24M	$3.13B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AMGN

Yahoo Finance Mon, 07 Sep 2026

Amgen's 7,297-Patient Heart Bet Just Inherited a Higher Bar

Novartis lowered the target biomarker without reducing events; olpasiran must prove the mechanism can still deliver.

Yahoo Finance Mon, 07 Sep 2026

Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal

AMGN shares fall as NVS' pelacarsen setback casts investor concern over whether olpasiran can deliver positive phase III outcome data.

Yahoo Finance Mon, 07 Sep 2026

Unlocking Opportunity: Dominate the Bi/Multispecific Drug in the Oncology Market with Confidence Now Available. Tracks 870+ Organizations and 1,400+ Drugs Across the Full Bi/Multispecific Oncology Pipeline

One-Year Analytical Tool Delivers Near-Real-Time Pipeline Alerts on 481 Targets, 350 Deals, and 1,100+ Funding Rounds as Amgen, Roche, and J&J Lead a Field That Saw 278 New Drugs in 2024/25 AloneDublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Th…

Yahoo Finance Fri, 04 Sep 2026

Amgen (AMGN) Says Repatha Reduced Mortality Before a First Heart Attack or Stroke. Can Earlier Use Expand the Market?

Amgen Inc. (NASDAQ:AMGN) reported that Repatha reduced the risk of all-cause mortality by 20% in a prespecified secondary analysis of the Phase 3 VESALIUS-CV trial. The study enrolled more than 12,000 high-risk adults without a previous hea…

Yahoo Finance Fri, 04 Sep 2026

AMGN's MariTide: Can Convenience Drive its Obesity Market Share?

Amgen's MariTide could target obesity with less frequent dosing, offering a convenience edge as competition from Lilly and Novo Nordisk intensifies.

Yahoo Finance hu, 03 Sep 2026

Why Is Amgen (AMGN) Up 8.6% Since Last Earnings Report?

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AMGN — Frequently Asked Questions

What is the current share price of Amgen Inc. (AMGN)?

As of 2026-09-07 16:24 PDT, Amgen Inc. (AMGN) trades at $437.23 on NasdaqGS. Its 52-week range is $263.86 to $444.12.

What is the market capitalisation of AMGN?

Amgen Inc. (AMGN) has a market capitalisation of $235.98B on NasdaqGS.

What is the P/E ratio of AMGN?

AMGN trades at a trailing price-to-earnings (P/E) ratio of 27.14. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 19.01.

Does AMGN pay a dividend?

Amgen Inc. (AMGN) currently offers a dividend yield of 2.49%.

What is the return on equity (ROE) of AMGN?

AMGN has a return on equity (ROE) of 91.47%. Its return on capital employed (ROCE) is 13.95%.

Is AMGN a good stock to buy?

This page provides a data-driven analysis of Amgen Inc. (AMGN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Amgen Inc. AMGN NDXSPXR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Amgen's 7,297-Patient Heart Bet Just Inherited a Higher Bar

Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal

Unlocking Opportunity: Dominate the Bi/Multispecific Drug in the Oncology Market with Confidence Now Available. Tracks 870+ Organizations and 1,400+ Drugs Across the Full Bi/Multispecific Oncology Pipeline

Amgen (AMGN) Says Repatha Reduced Mortality Before a First Heart Attack or Stroke. Can Earlier Use Expand the Market?

AMGN's MariTide: Can Convenience Drive its Obesity Market Share?

Why Is Amgen (AMGN) Up 8.6% Since Last Earnings Report?

AMGN — Frequently Asked Questions

What is the current share price of Amgen Inc. (AMGN)?

What is the market capitalisation of AMGN?

What is the P/E ratio of AMGN?

Does AMGN pay a dividend?

What is the return on equity (ROE) of AMGN?

Is AMGN a good stock to buy?

Explore More